Company Filing History:
Years Active: 1999-2025
Title: **The Innovative Contributions of Douglas Craig Hooper**
Introduction
Douglas Craig Hooper, an accomplished inventor based in Medford, NJ, has made significant strides in the field of cancer research. With a remarkable portfolio of 17 patents, his work focuses on advanced therapeutic methods that target various aspects of cancer treatment. His innovative approach not only addresses the challenges posed by cancer but also enhances therapeutic immunity in patients.
Latest Patents
Two of Douglas Craig Hooper's latest patents exemplify his pioneering research in treating cancers. The first patent discusses "Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes." This disclosure provides pharmaceutical compositions comprising nucleic acids designed to target IGF-1R expression in M2 cells, thereby facilitating the selective reduction of these cells and improving cancer treatment options. The ease of administration of this pharmaceutical composition enhances patient compliance, making it a promising candidate for systemic treatment.
The second patent focuses on "Methods and compositions for treating cancers using antisense." This development relates to utilizing antisense nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R) as a treatment for various cancers, including glioblastoma. The method involves administering the antisense either systemically or through an implantable irradiated biodiffusion chamber that houses tumor cells. This innovative approach is designed to stimulate an immune response that effectively targets tumors distally.
Career Highlights
Douglas Craig Hooper's career is marked by a commitment to advancing cancer research and developing innovative therapies. His extensive work has been recognized through numerous patents, contributing significantly to the scientific community's understanding of cancer treatment and patient care. As a leading researcher at Thomas Jefferson University, he continues to push the boundaries of innovation in medical science.
Collaborations
Throughout his career, Douglas has collaborated with esteemed colleagues, including David W. Andrews and Hilary Koprowski. These partnerships have fostered a collaborative environment that promotes sharing of ideas and expertise, ultimately enhancing the impact of their research on cancer therapies.
Conclusion
Douglas Craig Hooper exemplifies the spirit of innovation in cancer research. His 17 patents and groundbreaking methods significantly contribute to the fight against cancer, providing hope for improved therapeutic options and patient outcomes. With ongoing collaborations and a dedication to advancing medical science, Hooper's work is poised to drive further innovations in the field of oncology.